EVIMED 60 Evista Raloxifene HCL

EVIMED 60 (Raloxifene HCL) is classified as a selective estrogen receptor modulator (SERM). Primarily prescribed for women, it serves as a preventive and therapeutic measure against postmenopausal bone loss (osteoporosis). By decelerating bone loss and promoting bone strength, it effectively reduces the risk of fractures. Additionally, EVIMED 60 may offer a potential reduction in the likelihood of developing specific forms of breast cancer following menopause.

PACKAGE CONTENT:

1 Box of 2×25 Tablets, 60mg per Tablet.